letter
Totipotency/Pluripotency and Patentability
Article first published online: 10 APR 2008
DOI: 10.1634/stemcells.2008-0232
Copyright © 2008 AlphaMed Press
Additional Information
How to Cite
Denker, H.-W. (2008), Totipotency/Pluripotency and Patentability. STEM CELLS, 26: 1656–1657. doi: 10.1634/stemcells.2008-0232
Publication History
- Issue published online: 2 JAN 2009
- Article first published online: 10 APR 2008
- Manuscript Accepted: 4 APR 2008
- Manuscript Received: 10 MAR 2008
- Abstract
- Article
- References
- Cited By
Keywords:
- Embryonic stem cell totipotency;
- Human embryonic stem cells;
- Human embryos;
- Ethics;
- Patenting
Abstract
In their article entitled “Commentary: Is totipotency of a human cell a sufficient reason to exclude its patentability under the European law” (Stem Cells 2007;25:3026–3028), K.T. Vrtovec and B. Vrtovec conclude that arguments based on differentiation potential should not be an obstacle to patenting human embryonic stem cells (and related cells referred to as totipotent or pluripotent). While concentrating on formal legal aspects, however, these authors fail to consider a major biological and ethical argument already found in the literature, namely that an obstacle to patenting is to be seen in the potential of cells (e.g., of embryonic stem cell lines), if this potential allows (re)constitution of an embryo when tetraploid complementation is performed.
Disclosure of potential conflicts of interest is found at the end of this article.

1549-4918/asset/olbannerleft.jpg?v=1&s=699114e871887e6b838f6a1c657fe256cfe127a6)
1549-4918/asset/olbannerright.gif?v=1&s=603f8f2ab5cd9d4f783c231915608956af51aeea)
1549-4918/asset/cover.gif?v=1&s=51ac62b4272cd760b70f0cb1539035cc40743da6)